Person:
Noel, Maxence

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Noel

First Name

Maxence

Name

Noel, Maxence
Author's Publications: search.filters.isAuthorOfPublication.61dd9d85-e96f-4b94-ad9d-de6e438eeee5

Search Results

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Publication
    The Schizophrenia-Associated Variant in SLC39A8 Alters Protein Glycosylation in the Mouse Brain
    (Springer Science and Business Media LLC, 2022-03-08) Mealer, Robert; Williams, Sarah E.; Noel, Maxence; Yang, Bo; D'Souza, Alexandria; Nakata, Toru; Graham, Daniel B.; Creasey, Elizabeth A.; Cetinbas, Murat; Sadreyev, Ruslan; Scolnick, Edward; Woo, Christina; Smoller, Jordan; Xavier, Ramnik; Cummings, Richard
    A missense mutation (A391T) in the manganese transporter SLC39A8 is strongly associated with schizophrenia in genomic studies, though the molecular connection to the brain remains hypothetical. Human carriers of A391T have reduced serum manganese, altered plasma glycosylation, and brain MRI changes consistent with altered metal transport. Here, using a knock-in mouse model homozygous for A391T, we show that the schizophrenia-associated variant changes protein glycosylation in the brain. Glycosylation of Asn residues in glycoproteins (N-glycosylation) was most significantly impaired, with effects differing between regions. RNAseq analysis showed negligible regional variation, consistent with changes in the activity of glycosylation enzymes rather than gene expression. Finally, nearly one third of detected glycoproteins were differentially N-glycosylated in the cortex, including members of several pathways previously implicated in schizophrenia such as cell adhesion molecules and neurotransmitter receptors, and expressed across all cell types. These findings provide a mechanistic link between a risk allele and potentially reversible biochemical changes in the brain, furthering our molecular understanding of the pathophysiology of schizophrenia and a novel opportunity for therapeutic development.